Pfizer's Ibrance Fails to Significantly Extend Lives of Breast Cancer Patients

This weekend, Pfizer presented results at the American Society of Clinical Oncology (ASCO) 2022 annual meeting from the Phase III trial of Ibrance (palbociclib) in combination with letrozole. Ibrance, a first-line treatment for ER+, HER2- metastatic breast cancer, did not improve the overall survival rate in patients.